Mindmaze Secures $105 Million Financing, Led By Concord Health Partners, To Fund Growth On Heels Of Banner Year And Initiates American Hospital Association Partnership
Mindmaze Secures $105 Million Financing, Led By Concord Health Partners, To Fund Growth On Heels Of Banner Year And Initiates American Hospital Association Partnership
02/17/22, 1:00 PM
Location
lausanneMoney raised
$105 million
MindMaze (“the Company”), a global pioneer in the multibillion-dollar digital neurotherapeutics market, today announced it has secured a $105 million financing round to accelerate its global commercial growth plans, supercharge ongoing R&D and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide spectrum of neurological diseases.
Company Info
Location
lausanne, vaud, switzerland
Additional Info
MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain’s ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating a universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze’s pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients’ recovery from many critical neurological conditions. Founded in 2012 by CEO Tej Tadi, PhD, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai. For more information, please visit www.mindmaze.com.